Priscilla Chan

This paper introduces a gel-top culture model that replicates mesenchymal features of glioblastoma cells and identifies CK2 as a potential therapeutic target.

This paper evaluates the safety and efficacy of SHP1705, a CRY2 activator, in preclinical models and Phase I trials, showing improved efficacy against GBM stem cells and synergistic effects with a REV-ERB agonist.

This paper identifies a cis-regulatory mechanism in triple-negative breast cancer where targeting circadian transcription factors with small molecules represses a circadian transcriptional program, offering a new therapeutic strategy.